Sight Sciences (SGHT) to Release Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Sight Sciences Stock Performance

NASDAQ SGHT opened at $4.66 on Tuesday. The company has a current ratio of 11.01, a quick ratio of 10.50 and a debt-to-equity ratio of 0.33. The company has a 50 day moving average price of $6.10 and a 200 day moving average price of $6.27. Sight Sciences has a 52 week low of $1.58 and a 52 week high of $8.45.

Insider Activity

In other news, CEO Paul Badawi sold 12,727 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.99, for a total value of $76,234.73. Following the completion of the sale, the chief executive officer now directly owns 5,725,433 shares in the company, valued at $34,295,343.67. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Sight Sciences news, insider Matthew Link sold 21,831 shares of Sight Sciences stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $5.61, for a total transaction of $122,471.91. Following the completion of the sale, the insider now directly owns 663,550 shares in the company, valued at $3,722,515.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul Badawi sold 12,727 shares of Sight Sciences stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.99, for a total transaction of $76,234.73. Following the sale, the chief executive officer now owns 5,725,433 shares of the company’s stock, valued at approximately $34,295,343.67. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 97,357 shares of company stock worth $574,666 over the last three months. Insiders own 28.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Lake Street Capital downgraded shares of Sight Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $10.00 to $5.00 in a report on Monday. Citigroup upped their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a report on Wednesday, July 10th. Finally, Morgan Stanley upped their price objective on shares of Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a report on Monday, July 15th. Five analysts have rated the stock with a hold rating, According to MarketBeat, Sight Sciences has an average rating of “Hold” and a consensus target price of $6.00.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.